

Updated: 04/2025 PARP Approved: 06/2025

Prior Authorization Criteria **Bylvay (odevixibat)**

All requests for Bylvay (odevixibat) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of **cholestatic pruritis** caused by **progressive familial intrahepatic cholestasis (PFIC) or Alagille syndrome (ALGS)** and the following criteria is met:

- Member must be > 3 months old
- Must be prescribed by or in consultation with a hepatologist or gastroenterologist
- Must provide documentation of BOTH of the following:
 - o Genetic testing confirming the diagnosis
 - Moderate to severe pruritus
- Must provide documentation showing the member has tried and failed or had an intolerance or contraindication to ursodeoxycholic acid (Ursodiol)
- Must provide documentation showing the member has tried and failed or had an intolerance or contraindication to ONE of the following for symptomatic relief of pruritis:
 - o Bile acid sequestrants (i.e. cholestyramine, colesevelam, or colestipol)
 - o Rifampicin
 - o Antihistamine
- Must provide baseline documentation of BOTH of the following:
 - Liver function tests
 - o Fat-soluble vitamin levels
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 3 months
- Reauthorization criteria
 - o Must submit LFTs within past 3 months
 - o Must submit fat-soluble vitamin levels within past 3 months
 - Documentation of improvement of pruritus OR dosing plan for continued use if no documented clinical benefit
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 04/2025 PARP Approved: 06/2025

BYLVAY (ODEVIXIBAT) PRIOR AUTHORIZATION FORM

| <u> </u> | | | | aboratory test results, or chart document | ation |
|---|------------------------------|---------------|--------------------|--|----------|
| | ole to Highmark Wholecare Pl | • | | A: (888) 245-2049 00) 392-1147 Mon – Fri 8:30am to 5:00p | nm |
| ii needed, you may can to speak to | PROVIDER IN | | | 30) 392-1147 Moli – FII 8.30aiii to 3.00j |)111 |
| Requesting Provider: | I KOVIDEK IN | | ovider N | JDI. | |
| Provider Specialty: | | | Office Contact: | | |
| State license #: | | | Office NPI: | | |
| Office Address: | | | Office Phone: | | |
| Office Address. | | | Office Fax: | | |
| | MEMBER IN | | | | |
| Member Name: DOB: | | | | | |
| | | | er weight: Height: | | |
| REQUESTED DRUG INFORMATION | | | | | |
| Medication: Strength: | | | | | . |
| Directions: | Quantity: Refills: | | | | |
| Is the member currently receiving re- | quested medication? Yes | No | Date N | Medication Initiated: | |
| Billing Information | | | | | |
| This medication will be billed: at a pharmacy OR medically, JCODE: medically, JCODE: | | | | | |
| Place of Service: Hospital Provider's office Member's home Other | | | | | |
| Place of Service Information | | | | | |
| Name: | - moo or 202 (2 | NF | | | |
| Address: | | | Phone: | | |
| | | | | | |
| | MEDICAL HISTORY (C | omplete for A | LL req | uests) | |
| Diagnosis: ICD Code: | | | | | |
| Has genetic testing been completed to confirm the diagnosis? Yes No | | | | | |
| Is moderate to severe pruritis present? Yes No | | | | | |
| Have baseline LFTs been checked? Yes No | | | | | |
| Have baseline fat-soluble vitamin levels been checked? | | | | | |
| What has been tried? Check all that apply and provide the information below. | | | | | |
| Ursodiol Bile acid sequestrant (e.g. cholestyramine, colesevelam, colestipol) | | | | | |
| Rifampin Antihi | stamine | | | | |
| | CURRENT or PRE | | | | |
| Medication Name | Strength/ Frequency | Dates of The | erapy | Status (Discontinued & Why/Curre | ent) |
| | | | | | |
| | | | | | |
| | | | | | |
| | | RIZATION | | | |
| Have LFT's been checked within the | | No Dx | | | |
| Have fat-soluble vitamin levels been checked within the past 3 months? Yes No | | | | | |
| Has the member experienced an improvement of pruritis with treatment? Yes No SUPPORTING INFORMATION or CLINICAL RATIONALE | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Prescribing Provide | ar Signatura | | | Date | |
| Frescribing Provide | er orginature | | | Date | |
| | | | | | |